DelveInsight’s ‘Cytomegalovirus (CMV) Infections - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of CMV in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs having the potential to get launched in the forecast period, market share of the individual therapies, current and forecasted market size of Cytomegalovirus (CMV) Infections from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
Study Period: 2016-2027
Cytomegalovirus (CMV) Infections - Disease Understanding and Treatment Algorithm
The DelveInsight Cytomegalovirus (CMV) Infections market report gives the thorough understanding of the Cytomegalovirus (CMV) Infections by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Cytomegalovirus (CMV) Infections in the US, Europe, and Japan.
Cytomegalovirus (CMV) Infections Epidemiology
The Cytomegalovirus (CMV) Infections epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Sero Prevalence of Cytomegalovirus Infection in 7MM,Total Diagnosed CMV Patients in 7MM, Infants at High Risk of CMV, CMV Patients among Hematopoietic Stem Cell Transplants (HSCT), Number of Refractory CMV Patients after HSCT, Number of CMV Patients among Solid Organ Transplants (SOT),CMV Retinitis among HIV Patients) scenario of Cytomegalovirus (CMV) Infections in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to DelveInsight, the total sero- prevalent population of Cytomegalovirus (CMV) Infections was found to be 162,856,267 in the US in 2016.
Cytomegalovirus (CMV) Infections Drug Chapters
This segment of the Cytomegalovirus (CMV) Infections report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Currently, antiviral drugs are used to prevent CMV infection following transplant procedures. The drugs used to prevent/treat cytomegalovirus are valganciclovir, ganciclovir, cidofovir, foscarnet, or a combination etc. Ganciclovir (GCV) was the first antiviral agent approved for treatment of CMV disease, and remains the first-line treatment for CMV infection and CMV disease in transplant recipients. Valganciclovir (Valcyte) which is a prodrug of ganciclovir is the best drug for prophylaxis because it is effective and available in oral form, its high cost limits its use. Valganciclovir was approved in 2000 for treatment of CMV retinitis in AIDS patients and was later approved for prophylactic treatment of CMV in certain SOT recipients.
Four upcoming therapies are expected to enter the therapeutic market of Cytomegalovirus (CMV) Infections in 7MM during the forecast period (2018-2027). Detailed chapters of upcoming therapies like Cannabinoid receptor CB1 antagonists, Epidiolex (GW Pharmaceuticals) and Enzyme cholesterol 24-hydroxylase (CH24H) Inhibitor, TAK-935 (Takeda Pharmaceutical Company Limited) have also been covered in the report
Cytomegalovirus (CMV) Infections Market Outlook
The Cytomegalovirus (CMV) Infections market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Cytomegalovirus (CMV) Infections in 7MM was found to be USD 840.6 million in 2016.
Cytomegalovirus (CMV) Infections Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Cytomegalovirus (CMV) Infections Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Cytomegalovirus (CMV) Infections Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition
Cytomegalovirus (CMV) Infections Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Cytomegalovirus (CMV) Infections market
• Organize sales and marketing efforts by identifying the best opportunities for Cytomegalovirus (CMV) Infections market
• To understand the future market competition in the Cytomegalovirus (CMV) Infections market.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook